Stoke Therapeutics (STOK) News Today $11.31 -0.30 (-2.58%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from AnalystsNovember 17, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Buy" by BrokeragesStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and oNovember 17, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 8.3% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Trading Down 8.3% - What's Next?November 15, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases 36,240 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Los Angeles Capital Management LLC boosted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 54.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,005 shares of the company's stock afteNovember 15, 2024 | marketbeat.comComparing CV Sciences (OTCMKTS:CVSI) and Stoke Therapeutics (NASDAQ:STOK)November 11, 2024 | americanbankingnews.comWhat is HC Wainwright's Forecast for STOK FY2024 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share estimates for Stoke Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($2.00November 8, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for STOK EarningsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earningsNovember 8, 2024 | marketbeat.comWedbush Lifts Earnings Estimates for Stoke TherapeuticsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at Wedbush upped their FY2024 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Wedbush analyst L. Chico now forecasts that the company will earnNovember 8, 2024 | marketbeat.comOptimistic Buy Rating for Stoke Therapeutics: Strategic Focus on Zorevunersen and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comStoke Therapeutics’ Zorevunersen Shows Promising Efficacy in Reducing Seizures and Improving Quality of Life, Justifying Buy RatingNovember 6, 2024 | markets.businessinsider.comStoke Therapeutics Reports Q3 Results, Focuses on Phase 3 StudyNovember 6, 2024 | markets.businessinsider.comNeed To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) RevenuesNovember 6, 2024 | finance.yahoo.comStoke Therapeutics’ Promising Outlook: Buy Rating Backed by Positive Study Results and Strategic AdvancementsNovember 6, 2024 | markets.businessinsider.comStoke Therapeutics: Promising Growth Potential Backed by Strategic Advancements and Financial StabilityNovember 6, 2024 | markets.businessinsider.comStoke Therapeutics (NASDAQ:STOK) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday.November 6, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday.November 6, 2024 | marketbeat.comStoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesNovember 6, 2024 | finanznachrichten.deStoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.1% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Trading Down 4.1% - Time to Sell?November 5, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. reduced its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,312,479 shares of the company's stock after selling 155,723 shares during the perioOctober 27, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) is Skorpios Trust's Largest PositionSkorpios Trust lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 17.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,906,181 shares of the company's stock after selling 1,937,500 shaOctober 26, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 78.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 14,917 shares of the company's stock after selling 53,684 shares during the quarOctober 24, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by BrokeragesShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received a consensus rating of "Buy" from the nine research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommeOctober 23, 2024 | marketbeat.comQ4 EPS Forecast for Stoke Therapeutics Raised by AnalystStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Leerink Partnrs boosted their Q4 2024 earnings per share estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects thatOctober 18, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Upgraded to "Strong-Buy" by Leerink PartnrsLeerink Partnrs raised Stoke Therapeutics to a "strong-buy" rating in a research report on Friday.October 15, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up - Here's WhyStoke Therapeutics (NASDAQ:STOK) Shares Gap Up - Here's WhyOctober 14, 2024 | marketbeat.comLeerink Partners Begins Coverage on Stoke Therapeutics (NASDAQ:STOK)Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday. They issued an "outperform" rating and a $18.00 price objective on the stock.October 14, 2024 | marketbeat.comMillennium Management LLC Buys 243,083 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Millennium Management LLC raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 528.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 289,067 shares of the company's stock after purchasing anOctober 14, 2024 | marketbeat.comShort Interest in Stoke Therapeutics, Inc. (NASDAQ:STOK) Declines By 19.9%Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 6,980,000 shares, a decrease of 19.9% from the September 15th total of 8,710,000 shares. Based on an average daily volume of 551,400 shares, the short-interest ratio is currently 12.7 days.October 13, 2024 | marketbeat.comStoke Therapeutics assumed with an Outperform at LeerinkOctober 13, 2024 | finance.yahoo.comStoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic DiseasesOctober 12, 2024 | msn.comThe story of Stoke City’s shrinking pitch and how Arsene Wenger fought to get it changedOctober 12, 2024 | msn.comWarning to illegal Stoke-on-Trent drivers as new police team hit the streetsOctober 12, 2024 | msn.comWhy I'm confident Stoke City will score enough goals in new regime thanks to key changeOctober 12, 2024 | msn.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - What's Next?Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Time to Sell?October 10, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comHealthcare of Ontario Pension Plan Trust Fund Buys 1,123,500 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 426.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,387,200 shares of the company'October 4, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Marshall Wace LLPMarshall Wace LLP lifted its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 550.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,161,037 shares of the company's stock after purchasing anSeptember 28, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from AnalystsStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received an average rating of "Moderate Buy" from the seven research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy reSeptember 28, 2024 | marketbeat.comLynx1 Capital Management LP Has $70.05 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)Lynx1 Capital Management LP increased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 40.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,185,191 shares of the company's stock afSeptember 27, 2024 | marketbeat.comMajor Middlesbrough injury boost ahead of Stoke - and further relief for CarrickSeptember 26, 2024 | uk.sports.yahoo.comChampionship veteran's 'survive' warning to new Stoke City bossSeptember 26, 2024 | msn.com'St George!' - Stoke-on-Trent hero who spent decades helping children rememberedSeptember 26, 2024 | msn.comMiddlesbrough v Stoke CitySeptember 26, 2024 | bbc.co.ukPolice statement after baby boy dies in 'squalid Stoke-on-Trent home'September 26, 2024 | msn.comHow recruitment will work at Stoke City as Narcis Pelach 'joins process'September 25, 2024 | uk.news.yahoo.comJoin our Stoke City WhatsApp group for breaking news in Narcis Pelach eraSeptember 25, 2024 | msn.com'Stoke City Night' on BBC Radio StokeSeptember 25, 2024 | bbc.co.ukReferee delivers key verdict on controversial Hull City moment at Stoke CitySeptember 25, 2024 | hulldailymail.co.ukMen who took part in Stoke-on-Trent disorder jailedSeptember 24, 2024 | msn.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down Following Insider SellingStoke Therapeutics (NASDAQ:STOK) Shares Gap Down After Insider SellingSeptember 24, 2024 | marketbeat.com Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. STOK Media Mentions By Week STOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.770.46▲Average Medical News Sentiment STOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼47▲STOK Articles Average Week Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARCT News RVNC News MRSN News HRTX News STTK News TWST News LBPH News ARWR News PTGX News IDYA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts